Or Bruck

All Publications

• Pulmonary Hypertension and Hyperglycemia-Not a Sweet Combination. Diagnostics (Basel, Switzerland) Bruck, O., Pandit, L. M. 2024; 14 (11)

  Abstract

  Hyperglycemia and pulmonary hypertension (PH) share common pathological pathways that lead to vascular dysfunction and resultant cardiovascular complications. These shared pathologic pathways involve endothelial dysfunction, inflammation, oxidative stress, and hormonal imbalances. Individuals with hyperglycemia or pulmonary hypertension also possess shared clinical factors that contribute to increased morbidity from both diseases. This review aims to explore the relationship between PH and hyperglycemia, highlighting the mechanisms underlying their association and discussing the clinical implications. Understanding these common pathologic and clinical factors will enable early detection for those at-risk for complications from both diseases, paving the way for improved research and targeted therapeutics.

  View details for DOI 10.3390/diagnostics14111119

  View details for PubMedID 38893645

  View details for PubMedCentralID PMC11171670

• Lung, Pleura, and Diaphragm Point-of-Care Ultrasound. Seminars in ultrasound, CT, and MR Bruck, O., Naofal, A., Senussi, M. H. 2024; 45 (1): 120-131

  Abstract

  Thoracic Ultrasonography involves the ultrasonographic examination of the lungs, pleura, and diaphragm. This provides a plethora of clinical information during the point of care assessment of patients. The air filled lungs create consistent artifacts and careful examination and understanding of these artefactual signs can provide useful information on underlying clinicopathologic states. This review aims to provide a review of the ultrasound signs and features that can be seen in horacic ultrasonography and summarize the clinical evidence to support its use.

  View details for DOI 10.1053/j.sult.2024.01.001

  View details for PubMedID 38244897

• Acute exacerbation of interstitial lung disease in the intensive care unit: Principles of diagnostic evaluation and management. World journal of critical care medicine Hayat Syed, M. K., Bruck, O., Kumar, A., Surani, S. 2023; 12 (3): 153-164

  Abstract

  Interstitial lung disease (ILD) is typically managed on an outpatient basis. Critical care physicians manage patients with ILD in the setting of an acute exacerbation (ILD flare) causing severe hypoxia. The principles of management of acute exacerbation of ILD are different from those used to manage patients with acute respiratory distress syndrome from sepsis, etc. Selected patients may be candidates for aggressive measures like extracorporeal membrane oxygenation and lung transplantation, while almost all patients will benefit from early palliative care. This review focused on the types of ILD, diagnosis, and management pathways for this challenging condition.

  View details for DOI 10.5492/wjccm.v12.i3.153

  View details for PubMedID 37397591

  View details for PubMedCentralID PMC10308341

• Severe Monkeypox in Hospitalized Patients - United States, August 10-October 10, 2022 MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT Miller, M. J., Cash-Goldwasser, S., Marx, G. E., Schrodt, C. A., Kimball, A., Padgett, K., Noe, R. S., McCormick, D. W., Wong, J. M., Labuda, S. M., Borah, B. F., Zulu, I., Asif, A., Kaur, G., McNicholl, J. M., Kourtis, A., Tadros, A., Reagan-Steiner, S., Ritter, J. M., Yu, Y., Yu, P., Clinton, R., Parker, C., Click, E. S., Salzer, J. S., McCollum, A. M., Petersen, B., Minhaj, F. S., Brown, E., Fischer, M. P., Atmar, R. L., DiNardo, A. R., Xu, Y., Brown, C., Goodman, J., Holloman, A., Gallardo, J., Siatecka, H., Huffman, G., Powell, J., Alapat, P., Sarkar, P., Hanania, N. A., Bruck, O., Brass, S. D., Mehta, A., Dretler, A. W., Feldpausch, A., Pavlick, J., Spencer, H., Ghinai, I., Black, S. R., Hernandez-Guarin, L. N., Won, S. Y., Shankaran, S., Simms, A. T., Alarcon, J., O'Shea, J. G., Brooks, J. T., McQuiston, J., Honein, M. A., O'Connor, S. M., Chatham-Stephens, K., O'Laughlin, K., Rao, A. K., Raizes, E., Gold, J. A. W., Morris, S., CDC Severe Monkeypox Invest Team 2022; 71 (44): 1412-1417

  Abstract

  As of October 21, 2022, a total of 27,884 monkeypox cases (confirmed and probable) have been reported in the United States.§ Gay, bisexual, and other men who have sex with men have constituted a majority of cases, and persons with HIV infection and those from racial and ethnic minority groups have been disproportionately affected (1,2). During previous monkeypox outbreaks, severe manifestations of disease and poor outcomes have been reported among persons with HIV infection, particularly those with AIDS (3-5). This report summarizes findings from CDC clinical consultations provided for 57 patients aged ≥18 years who were hospitalized with severe manifestations of monkeypox¶ during August 10-October 10, 2022, and highlights three clinically representative cases. Overall, 47 (82%) patients had HIV infection, four (9%) of whom were receiving antiretroviral therapy (ART) before monkeypox diagnosis. Most patients were male (95%) and 68% were non-Hispanic Black (Black). Overall, 17 (30%) patients received intensive care unit (ICU)-level care, and 12 (21%) have died. As of this report, monkeypox was a cause of death or contributing factor in five of these deaths; six deaths remain under investigation to determine whether monkeypox was a causal or contributing factor; and in one death, monkeypox was not a cause or contributing factor.** Health care providers and public health professionals should be aware that severe morbidity and mortality associated with monkeypox have been observed during the current outbreak in the United States (6,7), particularly among highly immunocompromised persons. Providers should test all sexually active patients with suspected monkeypox for HIV at the time of monkeypox testing unless a patient is already known to have HIV infection. Providers should consider early commencement and extended duration of monkeypox-directed therapy†† in highly immunocompromised patients with suspected or laboratory-diagnosed monkeypox.§§ Engaging all persons with HIV in sustained care remains a critical public health priority.

  View details for Web of Science ID 000885918000001

  View details for PubMedID 36327164

  View details for PubMedCentralID PMC9639440

• Severe Monkeypox in Hospitalized Patients - United States, August 10-October 10, 2022. MMWR. Morbidity and mortality weekly report Miller, M. J., Cash-Goldwasser, S., Marx, G. E., Schrodt, C. A., Kimball, A., Padgett, K., Noe, R. S., McCormick, D. W., Wong, J. M., Labuda, S. M., Borah, B. F., Zulu, I., Asif, A., Kaur, G., McNicholl, J. M., Kourtis, A., Tadros, A., Reagan-Steiner, S., Ritter, J. M., Yu, Y., Yu, P., Clinton, R., Parker, C., Click, E. S., Salzer, J. S., McCollum, A. M., Petersen, B., Minhaj, F. S., Brown, E., Fischer, M. P., Atmar, R. L., DiNardo, A. R., Xu, Y., Brown, C., Goodman, J. C., Holloman, A., Gallardo, J., Siatecka, H., Huffman, G., Powell, J., Alapat, P., Sarkar, P., Hanania, N. A., Bruck, O., Brass, S. D., Mehta, A., Dretler, A. W., Feldpausch, A., Pavlick, J., Spencer, H., Ghinai, I., Black, S. R., Hernandez-Guarin, L. N., Won, S. Y., Shankaran, S., Simms, A. T., Alarcón, J., O'Shea, J. G., Brooks, J. T., McQuiston, J., Honein, M. A., O'Connor, S. M., Chatham-Stephens, K., O'Laughlin, K., Rao, A. K., Raizes, E., Gold, J. A., Morris, S. B. 2022; 71 (44): 1412-1417

  Abstract

  As of October 21, 2022, a total of 27,884 monkeypox cases (confirmed and probable) have been reported in the United States.§ Gay, bisexual, and other men who have sex with men have constituted a majority of cases, and persons with HIV infection and those from racial and ethnic minority groups have been disproportionately affected (1,2). During previous monkeypox outbreaks, severe manifestations of disease and poor outcomes have been reported among persons with HIV infection, particularly those with AIDS (3-5). This report summarizes findings from CDC clinical consultations provided for 57 patients aged ≥18 years who were hospitalized with severe manifestations of monkeypox¶ during August 10-October 10, 2022, and highlights three clinically representative cases. Overall, 47 (82%) patients had HIV infection, four (9%) of whom were receiving antiretroviral therapy (ART) before monkeypox diagnosis. Most patients were male (95%) and 68% were non-Hispanic Black (Black). Overall, 17 (30%) patients received intensive care unit (ICU)-level care, and 12 (21%) have died. As of this report, monkeypox was a cause of death or contributing factor in five of these deaths; six deaths remain under investigation to determine whether monkeypox was a causal or contributing factor; and in one death, monkeypox was not a cause or contributing factor.** Health care providers and public health professionals should be aware that severe morbidity and mortality associated with monkeypox have been observed during the current outbreak in the United States (6,7), particularly among highly immunocompromised persons. Providers should test all sexually active patients with suspected monkeypox for HIV at the time of monkeypox testing unless a patient is already known to have HIV infection. Providers should consider early commencement and extended duration of monkeypox-directed therapy†† in highly immunocompromised patients with suspected or laboratory-diagnosed monkeypox.§§ Engaging all persons with HIV in sustained care remains a critical public health priority.

  View details for DOI 10.15585/mmwr.mm7144e1

  View details for PubMedID 36327164

  View details for PubMedCentralID PMC9639440

• Diabetic Ketoacidosis as an Initial Presentation of Anti-PD-L1 Antibody Durvalumab-Induced Diabetes Mellitus Reid, S., Bruck, O. OXFORD UNIV PRESS. 2021

  View details for DOI 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A4863

  View details for Web of Science ID 001773961700018

• Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry. Immunologic research Bizjak, M., Bruck, O., Praprotnik, S., Dahan, S., Shoenfeld, Y. 2017; 65 (1): 164-167

  Abstract

  A 20-year-old man developed severe abdominal pain 1 week after being vaccinated with the first dose of quadrivalent human papillomavirus (HPV) vaccine (Gardasil®). Despite ongoing symptoms of nausea and pain, he received the second dose of the vaccine. Only 10 days later, laboratory results revealed significantly elevated pancreatic enzymes, and with concomitant abdominal pain and vomiting, he was diagnosed with acute pancreatitis. This case of acute pancreatitis after HPV vaccination is not a novel entity. Although confirming the relationship between pancreatitis and vaccine is challenging, some factors suggest a possible link, including the positive re-challenge upon repeated exposure to the vaccine, HPV vaccine as probable causal relationship to other autoimmune diseases and a probable mechanism of molecular mimicry. In conjunction with aluminum adjuvant, the induction of immunity through molecular mimicry may potentially culminate in production of cytotoxic autoantibodies with a particular affinity for pancreatic acinar cells.

  View details for DOI 10.1007/s12026-016-8823-9

  View details for PubMedID 27421720

• Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccine. Seminars in hematology Bizjak, M., Bruck, O., Kanduc, D., Praprotnik, S., Shoenfeld, Y. 2016; 53 Suppl 1: S48-50

  Abstract

  A 13-year-old girl developed immune thrombocytopenic purpura (ITP) and concomitant positive antiphospholipid antibodies (aPL) following vaccination with a quadrivalent human papillomavirus (HPV) vaccine. During the course of a disease, she developed clinical manifestation with bleeding and she was treated with intravenous immunoglobulins. Consequently, the number of her platelets remained critically low and she was put on corticosteroids and rituximab. Since then, her platelet count remain within the normal range, but her aPL are still present.

  View details for DOI 10.1053/j.seminhematol.2016.04.014

  View details for PubMedID 27312165

• Silicone implants and lymphoma: The role of inflammation. Journal of autoimmunity Bizjak, M., Selmi, C., Praprotnik, S., Bruck, O., Perricone, C., Ehrenfeld, M., Shoenfeld, Y. 2015; 65: 64-73

  Abstract

  The risk of hematological malignancies is mainly determined by genetic background, age, sex, race and ethnicity, geographic location, exposure to certain chemicals and radiation; along with the more recently proposed immune factors such as chronic inflammation, immunodeficiencies, autoimmunity, and infections. Paradigmatic examples include the development of lymphoma in Sjögren's syndrome and Hashimoto thyroiditis, gastric MALT lymphoma in Helicobacter pylori infection, or lymphomas associated with infections by Epstein-Barr virus, human herpes virus 8 (HHV 8) and leukemia/lymphoma virus 1 (HTLV-1). A growing number of reports indicates an increased risk of lymphoma, particularly of the anaplastic large cell (ALCL) type. The implants, specifically those used in the past, elicit chronic stimulation of the immune system against the prosthetic material. This is particularly the case in genetically susceptible hosts. We suggest that polyclonal activation may result in monoclonality in those at risk hosts, ultimately leading to lymphoma. We suggest that patients with an inflammatory response against silicone implants be monitored carefully.

  View details for DOI 10.1016/j.jaut.2015.08.009

  View details for PubMedID 26330346